Among the novel PD-L1 enhancers, we demonstrated that WNK3, a less characterized protein in cancer, is necessary and sufficient for the transactivation of PD-L1 through its kinase activity in JNK-dependent but IFN-γ/STAT3-independent mechanisms. Here, IFNG is linked to cancer.